Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director | May 28, 2019 | May 31, 2019 |
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Director | September 12, 2024 | September 13, 2024 |
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date May 28, 2019 · Filed May 31, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Vertex Global Healthcare Fund I PTE. LTD | 1,081,823 |
Reported balance
After 2019-05-28 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2019-05-28 · Conversion · Acquired 1,272,733 · Balance 1,081,823 F1: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Vertex Global Healthcare Fund I PTE. LTD | 1,207,410 |
Reported balance
After 2019-05-28 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2019-05-28 · Other · Acquired 141,668 · Balance 1,207,410 F1: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Vertex Global Healthcare Fund I PTE. LTD | 1,427,151 |
Reported balance
After 2019-05-28 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2019-05-28 · Conversion · Acquired 206,767 · Balance 1,427,151 F1: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. |
| Series B1 Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Vertex Global Healthcare Fund I PTE. LTD | 0 |
Reported balance
After 2019-05-28 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2019-05-28 · Conversion · Disposed 1,272,733 · Balance 0 F1: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. |
| Series B1 Preferred Shares WarrantsSEC Table II · derivative / convertible security | IndirectBy Vertex Global Healthcare Fund I PTE. LTD | 0 |
Reported balance
After 2019-05-28 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2019-05-28 · Other · Disposed 141,668 · Balance 0 F2: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering. F1: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. |
| Series B2 Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Vertex Global Healthcare Fund I PTE. LTD | 0 |
Reported balance
After 2019-05-28 transaction · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · 2019-05-28 · Conversion · Disposed 206,767 · Balance 0 F1: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date.
F2: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.
Bicara Therapeutics Inc.
Report date September 12, 2024 · Filed September 13, 2024
This filing explicitly reported no securities owned.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No securities beneficially ownedSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2026-05-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2019 Filed May 31, 2019 01:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries B2 Preferred Shares · Derivative | 206,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032918 · a4.xml · derivative · entry 7 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 0 Underlying: Ordinary Shares · 206,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | OtherSeries B1 Preferred Shares Warrants · Derivative | 141,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032918 · a4.xml · derivative · entry 6 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 0 Underlying: Ordinary Shares · 141,668 shares Expires not disclosed F2 · security: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering. F1 · derivative.exercise_price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.underlying: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries B1 Preferred Shares · Derivative | 1,272,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032918 · a4.xml · derivative · entry 5 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 0 Underlying: Ordinary Shares · 1,272,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 206,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032918 · a4.xml · nonDerivative · entry 3 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 1,621,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | OtherOrdinary Shares | 141,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032918 · a4.xml · nonDerivative · entry 2 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 1,414,401 F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 1,272,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032918 · a4.xml · nonDerivative · entry 1 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 1,272,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 10:05 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries B2 Preferred Shares · Derivative | 206,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032950 · a4a.xml · derivative · entry 6 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 0 Underlying: Ordinary Shares · 206,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 10:05 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | OtherSeries B1 Preferred Shares Warrants · Derivative | 141,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032950 · a4a.xml · derivative · entry 5 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 0 Underlying: Ordinary Shares · 141,668 shares Expires not disclosed F2 · security: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering. F1 · derivative.exercise_price: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.underlying: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 10:05 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries B1 Preferred Shares · Derivative | 1,272,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032950 · a4a.xml · derivative · entry 4 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 0 Underlying: Ordinary Shares · 1,272,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 10:05 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 206,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032950 · a4a.xml · nonDerivative · entry 3 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 1,427,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 10:05 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | OtherOrdinary Shares | 141,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032950 · a4a.xml · nonDerivative · entry 2 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 1,207,410 F1 · price: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 10:05 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 1,272,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032950 · a4a.xml · nonDerivative · entry 1 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Global Healthcare Fund I PTE. LTD Disclosed balance after: 1,081,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series B1 Preferred Share and Series B2 Preferred Share automatically converted into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 27, 2019 Filed May 31, 2019 01:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | PurchaseOrdinary Shares | 571,429 | $14.00 | $8,000,006.00 |
DisclosureSEC source: 0001104659-19-032918 · a4.xml · nonDerivative · entry 4 NG CAROLYN · CIK 0001777346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vertex Venture Management PTE LTD. Disclosed balance after: 571,429 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.